Crizanlizumab-tmca

From WikiMD's free health, diet & wellness encyclopedia
(Redirected from Adakveo)
Jump to navigation Jump to search

What is Crizanlizumab-tmca?

It is a monoclonal antibody medication developed by Novartis targeted towards P-selectin

What are the uses of this medicine?

It is indicated to reduce the frequency of vaso occlusive crises(VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.

How does this medicine work?

Crizanlizumab is a humanized IgG2 kappa monoclonal antibody that binds to P-selectin and blocks interactions with its ligands including P-selectin glycoprotein ligand 1

Who Should Not Use this medicine?

no contraindications

Is this medicine FDA approved?

The U.S. Food and Drug Administration (FDA) approved crizanlizumab

How should this medicine be used?

should be prepared and administered by a healthcare professional.

  • Administer ADAKVEO diluted solution by intravenous infusion over a period of 30 minutes through an intravenous line, which must contain a sterile, nonpyrogenic 0.2 micron inline filter.
  • No incompatibilities have been observed between ADAKVEO and infusion sets composed of PVC, polyethylene (PE-lined PVC), polyurethane (PU), and in-line filter membranes composed of polyethersulfone (PES, neutral and positively charged), positively charged polyamide (PA), and polysulphone (PSU).
  • Do not mix or coadminister with other drugs through the same intravenous line.
  • After administration of ADAKVEO, flush the line with at least 25 mL of 0.9% Sodium Chloride or 5% Dextrose Injection.

What are the dosage forms and brand names of this medicine?

  • Brand name: ADAKVEO
  • Injection: 100 mg/10 mL (10 mg/mL) as a clear to opalescent, colorless to slightly brownish-yellow solution in a single-dose vial.
  • Administer ADAKVEO 5 mg/kg by intravenous infusion over a period of 30 minutes at Week 0, Week 2, and every 4 weeks thereafter.

What should i do if i miss a dose?

  • consult your doctor and inform them

For health care professionals:

  • If a dose is missed, administer ADAKVEO as soon as possible.
  • If ADAKVEO is administered within 2 weeks after the missed dose, continue dosing according to the patient's original schedule.
  • If ADAKVEO is administered more than 2 weeks after the missed dose, continue dosing every 4 weeks thereafter.
  • ADAKVEO may be given with or without hydroxyurea.

What side effects can this medication cause?

What special precautions should I follow?

  • Monitor patients for signs and symptoms of infusion-related reactions, which may include :
  • Discontinue ADAKVEO infusion for severe reactions and institute appropriate medical care.

What to do in case of emergency/overdose?

Since crizanlizumab is given by a healthcare professional in a medical setting, an overdose is unlikely to occur

Can this medicine be used in pregnancy?

  • Based on data from animal studies, ADAKVEO has the potential to cause fetal harm when administered to a pregnant woman
  • ADAKVEO should only be used during pregnancy if the expected benefit to the patient justifies the potential risk to the fetus

Can this medicine be used in children?

  • can be used in children above 16 years
  • safety and efficacy below 16 years is not been established

What should I know about storage and disposal of this medication?

  • The single-dose vial has a rubber stopper and an aluminum cap with a plastic flip-off disk. Each 10 mL vial is made of Type 1 glass.
  • Store and transport refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light.
  • Do not shake. Do not freeze.

Cost and Coupons - Crizanlizumab-tmca

Reviews for Crizanlizumab-tmca

Learn more about Crizanlizumab-tmca

Latest research - Crizanlizumab-tmca

PubMed
Clinical trials

External links

Wikipedia
Medicine icon
Medicine icon

This WikiMD article Crizanlizumab-tmca is a stub. If you are familiar with the topic Crizanlizumab-tmca, you can help us. Paid editors welcome!

Latest research - Crizanlizumab-tmca

PubMed
Clinical trials
 

Crizanlizumab-tmca is part of WikiMD's free ^articles!

^Crizanlizumab-tmca (article) is provided for informational purposes only. No expressed or implied warranties as to the validity of content.
WikiMD is not a substitute for professional advice. By accessing and using WikiMD you agree to the terms of use.
Templates etc. when imported from Wikipedia, are licensed under CC BY-SA 3.0. See full disclaimers.
W8MD weight loss logo

Ad. Tired of being overweight?. W8MD's physician weight loss program can HELP. Tele medicine available